{"organizations": [], "uuid": "ba9c89d4ea8475a235b0462318fa87860154efa5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-vital-therapies-announces-upcoming-fourth-quarter-and-full-year-financial-results-conference-call-with-webcast-and.html", "country": "US", "domain_rank": 767, "title": "Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.016, "site_type": "news", "published": "2018-02-27T15:59:00.000+02:00", "replies_count": 0, "uuid": "ba9c89d4ea8475a235b0462318fa87860154efa5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-vital-therapies-announces-upcoming-fourth-quarter-and-full-year-financial-results-conference-call-with-webcast-and.html", "ord_in_thread": 0, "title": "Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "company", "sentiment": "none"}, {"name": "elad", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2017 financial results after the market closes on Tuesday, March 13, 2018 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.\nThe conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 7392256. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/ . The webcast will be archived on the Company's website shortly after completion of the call.\nFor those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on March 13, 2018 to 7:30 p.m. ET on March 20, 2018. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 7392256.\nUpcoming Investor Conference\nAdditionally, the Company will be presenting at the Raymond James 39th Annual Institutional Investors Conference Orlando, FL on Monday, March 5th at 2:15 PM Eastern. A live webcast of the Company's presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/ . An archive of the presentation will be available for replay following the conference.\nAbout Vital Therapies, Inc.\nVital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.\nContact:\nVital Therapies, Inc.\nAl Kildani\nVice President, Investor Relations and Business Development\n858-673-6840\nakildani@vitaltherapies.com\nSource:Vital Therapies, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/27dd26df-cb68-4a6f-b782-dc59e48795ea", "https://www.globenewswire.com/Tracker?data=kd-hMrDGX0ExHTpI6CGFiLK-3IswsCQILunqlfLTgtjMu1x6Cys5luP2B-a3ry6vvupLjcCI-YYwvsJIqzAPXvezGD3hVCa_o6ocmobGC8U=", "https://www.globenewswire.com/Tracker?data=kd-hMrDGX0ExHTpI6CGFiLK-3IswsCQILunqlfLTgtiOXJhnCzSeykGI_y2CrSNumJKToDSTXkT79AxVRi9Zpb3bgqf88K8TRn5yuoIVY24=", "http://ir.vitaltherapies.com/", "https://www.globenewswire.com/Tracker?data=47UqswD-0Oc6nOYlLxiWj_2kMIWc2Cnm-LulHyaSdy3bvmbUi0BuE1WIqrLrPHVOAnZHMHT68rNaDWTFtaaw_8y8tIRo5vkgDcv7h-sCqWDxWaIk5NFgVZfP2eiCHnjc"], "published": "2018-02-27T15:59:00.000+02:00", "crawled": "2018-02-27T17:31:04.029+02:00", "highlightTitle": ""}